Pediatric Depression Studies Currently Recruiting.
Pediatric Depression Studies Currently Recruiting.
| No | NCT # | Abbreviated Study Title | Age (y) | # Pts/Centers |
|---|---|---|---|---|
| 1 | NCT03395353 | Long-term S study of duloxetine hydrochloride in Japanese children and adolescents with depressive disorder | 9–17 | 100/? |
| 2 | NCT03315793 | DB S&E study of duloxetine hydrochloride versus placebo in Japanese children and adolescents with depressive disorder | 9–17 | 148/? |
| 3 | NCT03665038 | MC, DB, PC study on E, S, T, PK of brexanolone in adolescent female subjects with postpartum depression | 15–17 | 80/13 |
| 4 | NCT02709655 | Interventional, R, DB, PC active reference (fluoxetine) fixed-dose study of vortioxetine in pts 7–11 y with MDD | 7–11 | 600/133 |
| 5 | NCT03569475 | DB, PAC, S&E levomilnacipran ER study in pts 7–17 y with MDD | 7–17 | 480/46 |
| 6 | NCT02431806 | DB, PAC, S&E levomilnacipran ER study in pts with MDD | 12–17 | 660/91 |
| 7 | NCT03185819 | DB, R psychoactive PC, E&S study of 3 doses of IN esketamine plus comprehensive SoC for rapid symptom reduction of MDD, including suicidal ideation, in imminent risk for suicide | 12–17 | 145/56 |
DB, double blind; E, efficacy; ER, extended release; IN, intranasal; MC, multicenter; MDD, major depressive disorder; NCT#, national clinical trial # in www.clinicaltrials.gov; PAC, placebo- and active controlled; PC, placebo-controlled; PK, pharmacokinetics; pts, patients; R, randomized; S, safety; S&E, safety and efficacy; SoC, standard of care; T, tolerability; y, year.